alpha-synuclein and Atherosclerosis

alpha-synuclein has been researched along with Atherosclerosis* in 3 studies

Reviews

2 review(s) available for alpha-synuclein and Atherosclerosis

ArticleYear
Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia.
    Journal of neurology, neurosurgery, and psychiatry, 2013, Volume: 84, Issue:7

    Although resting tremor, cogwheel rigidity, hypokinesia/bradykinesia and postural instability usually dominate the clinical picture of sporadic Parkinson's disease (PD), both clinical and epidemiological data reveal that a wide variety of additional symptoms impair patients' quality of life considerably, parallel to the chronic progressive neurodegenerative movement disorder. Autopsy based retrospective studies have shown that α-synuclein immunoreactive Lewy pathology (LP) develops in the locus coeruleus (LC) of patients with neuropathologically confirmed sporadic PD, as well as in individuals with incidental (prodromal or premotor) Lewy body disease but not in age and gender matched controls. Using five case studies, this review discusses the possible role of LP (axonopathy, cellular dysfunction and nerve cell loss) in the LC, catecholaminergic tract and related circuitry in the development of PD-related dementia. The contribution of noradrenergic deficit to cognitive dysfunction in PD has been underappreciated. Noradrenergic therapeutic interventions might not only alleviate depressive symptoms and anxiety but also delay the onset of cognitive decline.

    Topics: Aged; Aged, 80 and over; alpha-Synuclein; Atherosclerosis; Autopsy; Brain; Dementia; Disease Progression; Female; Humans; Lewy Body Disease; Locus Coeruleus; Male; Nerve Net; Norepinephrine; Parkinson Disease; REM Sleep Behavior Disorder; Sleep Initiation and Maintenance Disorders

2013
Small molecule oxidation products trigger disease-associated protein misfolding.
    Accounts of chemical research, 2006, Volume: 39, Issue:9

    Oxidative stress and inflammation are risk factors for both the development of alpha-synucleinopathies, such as Parkinson's disease and dementia with Lewy bodies, and Alzheimer's disease, the two most common neurodegenerative disorders. These diseases are associated with the neurotoxic deposition of misassembled alpha-synuclein and amyloid-beta (Abeta) peptides, respectively. Both occur sporadically, that is, without detectable disease-related mutations, in the vast majority of cases. Small molecule oxidation products, especially secosterols derived from cholesterol and 4-hydroxynonenal derived from lipid peroxidation, found in afflicted brains, accelerate the misassembly of both Abeta and alpha-synuclein. This Account explores the mechanism of small molecule oxidation product-mediated protein misassembly and possible intervention strategies.

    Topics: Aldehydes; alpha-Synuclein; Alzheimer Disease; Amyloid; Atherosclerosis; Biopolymers; Cholesterol; Humans; Inflammation; Lipid Peroxidation; Oxidation-Reduction; Oxidative Stress; Protein Folding

2006

Other Studies

1 other study(ies) available for alpha-synuclein and Atherosclerosis

ArticleYear
Calpain-mediated ABCA1 degradation: post-translational regulation of ABCA1 for HDL biogenesis.
    Biochimica et biophysica acta, 2012, Volume: 1821, Issue:3

    Helical apolipoproteins remove cellular phospholipid and cholesterol to generate nascent HDL and this reaction is the major source of plasma HDL. ABCA1 is mandatory and rate-limiting for this reaction. Besides regulation of the gene expression by transcriptional factors including LXR, AP2 and SREBP, the ABCA1 activity is regulated post-translationally by calpain-mediated proteolytic degradation of ABCA1 protein that occurs in the early endosome after its endocytosis. When the HDL biogenesis reaction is ongoing as helical apolipoproteins interact with ABCA1, ABCA1 becomes resistant to calpain and is recycled to cell surface after endocytosis. Biogenesis of HDL is most likely to take place on cell surface. Clearance rate of ABCA1 by this mechanism is also retarded by various factors that interact with ABCA1, such as α1-syntrophin, LXRβ and calmodulin. Physiological relevance of the retardation by these factors is not entirely clear. Pharmacological inhibition of the calpain-mediated ABCA1 degradation results in the increase of the ABCA1 activity and HDL biogenesis in vitro and in vivo, and potentially suppresses atherogenesis. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010).

    Topics: alpha-Synuclein; Animals; Aorta; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; BALB 3T3 Cells; Calmodulin; Calpain; Endocytosis; Endosomes; Lipoproteins, HDL; Liver X Receptors; Mice; Orphan Nuclear Receptors; Protein Processing, Post-Translational; Protein Transport; Proteolysis; Quinones; Rabbits

2012